HeartFlow(NASDAQ) HTFL

Heartflow helps doctors see inside a patient's heart without using surgery.

Its software uses artificial intelligence to find blockages in blood vessels.

This technology helps medical teams plan the best treatments for patients.

What Is in the Box?

• FFRCT Analysis: Software that creates 3D heart models to measure blood flow; generates almost all of the company's revenue.
• Plaque Analysis: A tool used to identify and measure the buildup of fatty materials in heart arteries.
• Heartflow Platform: A cloud-based system that turns medical scans into actionable data for physicians.

Building a Bigger Footprint

• Completed an initial public offering in August 2025 to raise $364 million in gross proceeds.
• Obtained clearance from the U.S. Food and Drug Administration for the Plaque Analysis tool in October 2022.
• Entered a sublease agreement with a third-party tenant for its Mountain View facility in March 2026.
• Received a civil investigative demand from the U.S. Department of Justice in October 2025 regarding marketing activities.

How Heartflow Stands Out

The company combines artificial intelligence with computational fluid dynamics, which is the study of how liquids move, to create personalized heart maps. This non-invasive method replaces traditional tests that often require physical entry into the body.

The Numbers Behind the Scans

• Revenue reached $52.6 million in Q1 2026, up 41.3% from Q1 2025.
• Gross profit was $42.2 million in Q1 2026, up 50.9% year-over-year.
• Net loss narrowed to $27.4 million in Q1 2026, representing a 15.4% improvement from the previous year.
• Cash, equivalents, and investments totaled $254.9 million as of March 31, 2026.

Evolution of Heart Care

Heartflow has moved from a private research firm to a public medical technology provider focused on AI-driven diagnostics. Its growth depends on moving beyond its original blood-flow tool into more complex plaque analysis services.